8-K: Allurion Technologies Appoints Milena Alberti-Perez to Board as Audit Committee Chair

Allurion Technologies has appointed Milena Alberti-Perez to its Board of Directors as a Class III director and Audit Committee Chair, effective March 11, 2024.

Summary

• Allurion Technologies appointed Milena Alberti-Perez to its Board of Directors as a Class III director, effective March 11, 2024.
• Ms. Alberti-Perez will also serve as the Chair of the Audit Committee.
• This appointment ensures Allurion's compliance with the New York Stock Exchange listing requirement 303A.07, which mandates at least three independent directors on the Audit Committee.
• The board has determined that Ms. Alberti-Perez is independent according to NYSE listing standards and SEC rules.
• Ms. Alberti-Perez's compensation will align with the company's existing non-employee director compensation policy.
• Ms. Alberti-Perez has previously served as CFO at Getty Images and Penguin Random House, where she oversaw a global business generating over $3 billion in annual sales.

Sentiment

Score: 8

Explanation: The document reflects a positive development with the appointment of a highly qualified individual to the board, which is generally viewed favorably by investors.

Positives

• The appointment of Ms. Alberti-Perez brings a highly experienced financial executive to the board.
• Her appointment ensures compliance with NYSE listing requirements.
• Ms. Alberti-Perez's experience at companies like Getty Images and Penguin Random House, with over $3 billion in annual sales, suggests she has a strong financial background.
• Her current roles at Digimarc and Pitney Bowes demonstrate her ongoing involvement in corporate governance and financial oversight.

Future Outlook

The company anticipates that Ms. Alberti-Perez's experience will be invaluable as Allurion furthers its mission to treat obesity.

Management Comments

• Dr. Shantanu Gaur, Allurion Founder and CEO, stated that Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader.
• Ms. Alberti-Perez said she is thrilled to join Allurion at a pivotal stage of its journey as a public company.

Industry Context

This appointment reflects a focus on strengthening corporate governance and financial oversight, which is a common trend for public companies, especially those listed on major exchanges like the NYSE.

Comparison to Industry Standards

• The appointment of an independent director to chair the audit committee is a standard practice for companies listed on the NYSE, aligning with best practices in corporate governance.
• Many companies in the healthcare and medical device sector, such as Medtronic and Boston Scientific, also maintain similar board structures with independent audit committee chairs.

Management Changes

Stakeholder Impact

• Shareholders will likely view this appointment positively as it strengthens the company's corporate governance.
• Employees may see this as a sign of stability and growth for the company.
• Customers and suppliers may not be directly impacted by this change.

Key Dates

Keywords

Board of Directors, Audit Committee, Milena Alberti-Perez, Corporate Governance, NYSE Compliance, Financial Leadership, Independent Director